is zepbound glp 1 agonist GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness What Is Zepbound (tirzepatide)? Uses,

Murphy G

Initially approval was for an injectable version, but in September 2019 an oral form, called Rybelsus, was approved in the US and then in the European Union in April 2020

In a randomized trial using PET-MRI to assess carotid plaque inflammation, semaglutide did not show a significant difference versus placebo on the prespecified primary plaque-inflammation endpointslikely influenced by low baseline inflammatory burden in a well-treated population. How to interpret this: Imaging studies like this are helpful for understanding mechanisms and terminology (e.g., atherosclerotic inflammation, PET-MRI plaque imaging), but they do not establish semaglutide as a direct vascular inflammation imaging reducer in general clinical use based on current evidence. 5) They Improve Kidney Outcomes in High-Risk Populations (Semaglutide) By improving glycemic control and metabolic stress, GLP-1 therapies can reduce kidney risk in susceptible patients

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

Mehdi SF, Pusapati S, Khenhrani RR, Farooqi MS, Sarwar S, Alnasarat A, et al